US Stem Cell Inc (OTCMKTS:USRM) is a stock on the move in a major way. USRM has been trending sharply higher over the past four months, breaking above major moving averages and accelerating on its rounded upward trajectory in what looks like the beginnings of a potential parabolic advance, from a technical perspective. The trend is now facing up to a key technical hurdle: a gap-fill of the large drop last seen down through the $0.08/share level back in June of 2017. That gap has gone unfilled until last month when the level was tested and rejected. Now, shares are pushing back up to test it again as a possible breakout trigger.
The trend has been pushed along by core tech items such as its recent announcement that it has successfully demonstrated a 99 percent reduction in-human of the severity of psoriasis using a patient’s autologous stem cells. According to the release, “the scientific paper, which is authored by USRM Chief Science Officer Dr. Kristin Comella and her USRM colleagues, is published in the International Medical Case Reports Journal, 2018:11 59-64. To the best of USRM management’s knowledge, this is the first result in the world published using stromal vascular fraction (SVF) and autologous stem cells in the successful treatment of psoriasis.”
US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the body’s own healing potential, we may be able to reverse damaged tissue to normal function.
The company’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.
According to company materials, “USRM is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.”
Find out when $USRM reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, USRM shares have been warming up and approaching potential red-hot status as the stock moves to test key resistance areas in its recent upward trend. We have been seeing some signs that its core R&D IP narrative has been progressing, powering the move.
“This is a breakthrough for the more than 7 million Americans suffering from psoriasis, and is another example of how a patient’s own stem cells offer healing modalities for autoimmune conditions,” said Dr. Comella. “Although we require additional studies to further develop more extensive protocol in treating patients with this condition, this is a benchmark indicating there is significant reason to believe the use of autologous stem cells is beneficial in combating this disease.”
Recent action has seen 73% added to share values of the name over the past month of action. Furthermore, the name has witnessed a pop in interest, as transaction volume levels have recently pushed 78% over the long run average.
Earning a current market cap value of $28M, USRM has a stash ($957K) of cash on the books, which compares with about $3.2M in total current liabilities. USRM is pulling in trailing 12-month revenues of $5M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 106.4%. This may be a very interesting story and we will look forward to updating it again soon. Sign-up for continuing coverage on shares of $USRM stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $USRM, either long or short, and we have not been compensated for this article.